Inhibiting the JAK2/STAT3/HMGCS2 signaling pathway with ruxolitinib and S3I-201 reversed cardiac dysfunction, mitochondrial dysfunction, and oxidative stress in hyperuricemic mice.
Does inhibiting the JAK2/STAT3/HMGCS2 pathway improve mitochondrial and cardiac function in hyperuricemia-induced cardiac dysfunction?
The JAK2/STAT3/HMGCS2 pathway mediates hyperuricemia-induced cardiac dysfunction, and its inhibition offers a potential therapeutic strategy for mitigating high uric acid-induced cardiac damage.
p-value: p=<0.05
BACKGROUND: High uric acid levels play a critical role in cardiovascular disease pathophysiology, being closely linked to their occurrence, progression, and prognosis. To enhance prevention and treatment of hyperuricemia-related cardiovascular diseases, understanding underlying mechanisms and identifying novel therapeutic targets are essential. METHODS: A hyperuricemic mouse model was established, and transcriptomic analysis of myocardial tissue was conducted using RNA sequencing. The role of HMGCS2 in hyperuricemia-induced cardiomyocytes was investigated through HMGCS2 knockout. The transcriptional regulation of HMGCS2 by STAT3 was explored via STAT3 knockdown, overexpression, and dual-luciferase reporter assays. To further elucidate the role of the JAK2/STAT3/hmgcs2 signaling pathway in hyperuricemia-induced cardiomyocytes, we overexpressed HMGCS2 while intervening in the JAK2/STAT3 pathway in vitro. The therapeutic potential of targeting the JAK2/STAT3/HMGCS2 pathway was evaluated in hyperuricemic mice using STAT3 and JAK inhibitors to assess effects on cardiac dysfunction. RESULTS: RNA sequencing showed significant upregulation of HMGCS2 mRNA in hyperuricemic mouse cardiac tissue. Increased HMGCS2 protein levels were observed in cardiac tissue and AC16 cardiomyocytes. HMGCS2 knockdown alleviated uric acid-induced mitochondrial dysfunction, oxidative stress, and abnormal energy metabolism in AC16 cardiomyocytes. And high uric acid levels activate the IL-6/JAK2/STAT3 signaling pathway in AC16 cardiomyocytes, which regulates HMGCS2 expression. By modulating JAK2 and STAT3 expression and subsequently overexpressing HMGCS2, we identified the involvement of the JAK2/STAT3/HMGCS2 pathway in uric acid-induced mitochondrial dysfunction, oxidative stress, and energy metabolism abnormalities in AC16 cardiomyocytes. In vitro experiments demonstrated that intervention with the ruxolitinib and S3I-201 could ameliorate mitochondrial dysfunction, oxidative stress, and ATP levels in the heart tissue of hyperuricemic mice. Moreover, these treatments also reversed cardiac function abnormalities. CONCLUSIONS: The JAK2/STAT3/HMGCS2 pathway may contributes to uric acid-induced cardiac dysfunction by affecting mitochondrial function, oxidative stress, and ATP metabolism, offering a potential therapeutic strategy for mitigating high uric acid-induced cardiac damage.
Peng et al. (Tue,) conducted a other in Hyperuricemia-induced cardiac dysfunction (n=25). Ruxolitinib and S3I-201 vs. Hyperuricemia vehicle control was evaluated on Cardiac function (LVEF, LVFS) and mitochondrial function (p=<0.05). Inhibiting the JAK2/STAT3/HMGCS2 signaling pathway with ruxolitinib and S3I-201 reversed cardiac dysfunction, mitochondrial dysfunction, and oxidative stress in hyperuricemic mice.